Dendritic cells in Asthma: A target for novel therapeutics?

Drug Discovery Today: Therapeutic Strategies

Volumn 3, Issue 3, 2006, Pages 299-307

  van Rijt, Leonie S ^a   Lambrecht, Bart N ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALLERGEN; ANTIASTHMATIC AGENT; CHEMOKINE RECEPTOR CCR7; CORTICOSTEROID; CPG OLIGODEOXYNUCLEOTIDE; DENDRITIC CELL VACCINE; DEXAMETHASONE; DNA; GAMMA INTERFERON; IMMUNOGLOBULIN E ANTIBODY; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 4; LEUKOTRIENE; LEUKOTRIENE RECEPTOR; LEUKOTRIENE RECEPTOR BLOCKING AGENT; OMALIZUMAB; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PHOSPHODIESTERASE IV; PHOSPHODIESTERASE IV INHIBITOR; PRANLUKAST; PROTEIN KINASE SYK; PROTEIN KINASE SYK INHIBITOR; ROFLUMILAST; ROSIGLITAZONE; TSUKUBAENOLIDE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UNINDEXED DRUG; VAF 347; VERLUKAST;

ANTIGEN PRESENTING CELL; ANTIMICROBIAL ACTIVITY; ASTHMA; CELL DEATH; CELL DIFFERENTIATION; CELL FUNCTION; CELL INTERACTION; CELL MATURATION; CELL MIGRATION; CELL POLARITY; CLINICAL TRIAL; DENDRITIC CELL; DRUG EFFICACY; DRUG TARGETING; EFFECTOR CELL; HUMAN; IMMUNE DEFICIENCY; IMMUNE RESPONSE; INFLAMMATION; NONHUMAN; REGULATORY MECHANISM; REVIEW; SENSITIZATION; T LYMPHOCYTE; TARGET CELL; TH2 CELL; UNSPECIFIED SIDE EFFECT;

EID: 33751160057     PISSN: 17406773     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ddstr.2006.08.006     Document Type: Review

References (62)

1. Lambrecht B.N., and Hammad H. Taking our breath away: dendritic cells in the pathogenesis of asthma. Nat. Rev. Immunol. 3 (2003) 994-1003
2. van Rijt L.S., et al. In vivo depletion of lung CD11c+ dendritic cells during allergen challenge abrogates the characteristic features of asthma. J. Exp. Med. 201 (2005) 981-991
3. Upham J.W., et al. Rapid response of circulating myeloid dendritic cells to inhaled allergen in asthmatic subjects. Clin. Exp. Allergy 32 (2002) 818-823
4. Moller G.M., et al. Increased numbers of dendritic cells in the bronchial mucosa of atopic asthmatic patients: downregulation by inhaled corticosteroids. Clin. Exp. Allergy 26 (1996) 517-524
5. Lambrecht B.N., et al. Myeloid dendritic cells induce Th2 responses to inhaled antigen, leading to eosinophilic airway inflammation. J. Clin. Invest. 106 (2000) 551-559
6. De Heer H.J., et al. Essential role of lung plasmacytoid dendritic cells in preventing asthmatic reactions to harmless inhaled antigen. J. Exp. Med. 200 (2004) 89-98
7. Lambrecht B.N. An unexpected role for the anaphylatoxin C5a receptor in allergic sensitization. J. Clin. Invest. 116 (2006) 628-632
8. Kohl J., et al. A regulatory role for the C5a anaphylatoxin in type 2 immunity in asthma. J. Clin. Invest. 116 (2006) 783-796
9. London C.A., et al. Functional responses and costimulator dependence of memory CD4+ T cells. J. Immunol. 164 (2000) 265-272
10. Huh J.C., et al. Bidirectional interactions between antigen-bearing respiratory tract dendritic cells (DCs) and T cells precede the late phase reaction in experimental asthma: DC activation occurs in the airway mucosa but not in the lung parenchyma. J. Exp. Med. 198 (2003) 19-30
11. Bellini A., et al. Intraepithelial dendritic cells and selective activation of Th2-like lymphocytes in patients with atopic asthma. Chest 103 (1993) 997-1005
12. Vermaelen K.Y., et al. Matrix metalloproteinase-9-mediated dendritic cell recruitment into the airways is a critical step in a mouse model of asthma. J. Immunol. 171 (2003) 1016-1022
13. Vermaelen K.Y., et al. Specific migratory dendritic cells rapidly transport antigen from the airways to the thoracic lymph nodes. J. Exp. Med. 193 (2001) 51-60
14. van Rijt L.S., et al. Allergen-induced accumulation of airway dendritic cells is supported by an increase in CD31(hi)Ly-6C(neg) bone marrow precursors in a mouse model of asthma. Blood 100 (2002) 3663-3671
15. Harris N.L., et al. Differential T cell function and fate in lymph node and nonlymphoid tissues. J. Exp. Med. 195 (2002) 317-326
16. Hackstein H., and Thomson A.W. Dendritic cells: emerging pharmacological targets of immunosuppressive drugs. Nat. Rev. Immunol. 4 (2004) 24-34
17. Lawrence T.E., et al. Fluticasone propionate and pentamidine isethionate reduce airway hyperreactivity, pulmonary eosinophilia and pulmonary dendritic cell response in a guinea pig model of asthma. J. Pharmacol. Exp. Ther. 284 (1998) 222-227
18. Woltman A.M., et al. The effect of calcineurin inhibitors and corticosteroids on the differentiation of human dendritic cells. Eur. J. Immunol. 30 (2000) 1807-1812
19. Matyszak M.K., et al. Differential effects of corticosteroids during different stages of dendritic cell maturation. Eur. J. Immunol. 30 (2000) 1233-1242
20. Saeki S., et al. Effects of antiasthmatic agents on the functions of peripheral blood monocyte-derived dendritic cells from atopic patients. J. Allergy Clin. Immunol. 114 (2004) 538-544
21. Vieira P.L., et al. Glucocorticoids inhibit bioactive IL-12p70 production by in vitro-generated human dendritic cells without affecting their T cell stimulatory potential. J. Immunol. 161 (1998) 5245-5251
22. Karagiannidis C., et al. Glucocorticoids upregulate FOXP3 expression and regulatory T cells in asthma. J. Allergy Clin. Immunol. 114 (2004) 1425-1433
23. Xystrakis E., et al. Reversing the defective induction of IL-10-secreting regulatory T cells in glucocorticoid-resistant asthma patients. J. Clin. Invest. 116 (2006) 146-155
24. Gregori S., et al. Regulatory T cells induced by 1 alpha, 25-dihydroxyvitamin D3 and mycophenolate mofetil treatment mediate transplantation tolerance. J. Immunol. 167 (2001) 1945-1953
25. Till S.J., et al. Recruitment of CD1a+ Langerhans cells to the nasal mucosa in seasonal allergic rhinitis and effects of topical corticosteroid therapy. Allergy 56 (2001) 126-131
26. Xing N., et al. Distinctive dendritic cell modulation by vitamin D(3) and glucocorticoid pathways. Biochem. Biophys. Res. Commun. 297 (2002) 645-652
27. Banchereau J., et al. Immunobiology of dendritic cells. Annu. Rev. Immunol. 18 (2000) 767-811
28. Lee H.J., et al. Increased expression of MIP-3alpha/CCL20 in peripheral blood mononuclear cells from patients with ulcerative colitis and its down-regulation by sulfasalazine and glucocorticoid treatment. Inflamm. Bowel Dis. 11 (2005) 1070-1079
29. Brokaw J.J., et al. Glucocorticoid-induced apoptosis of dendritic cells in the rat tracheal mucosa. Am. J. Respir. Cell Mol. Biol. 19 (1998) 598-605
30. Fokkens W.J., et al. Allergic rhinitis and inflammation: the effect of nasal corticosteroid therapy. Allergy 52 36 Suppl. (1997) 29-32
31. Hammad H., et al. Prostaglandin D2 inhibits airway dendritic cell migration and function in steady state conditions by selective activation of the D prostanoid receptor 1. J. Immunol. 171 (2003) 3936-3940
32. Hammad H., et al. Activation of peroxisome proliferator-activated receptor-gamma in dendritic cells inhibits the development of eosinophilic airway inflammation in a mouse model of asthma. Am. J. Pathol. 164 (2004) 263-271
33. Robbiani D.F., et al. The leukotriene C(4) transporter MRP1 regulates CCL19 (MIP-3beta, ELC)-dependent mobilization of dendritic cells to lymph nodes. Cell 103 (2000) 757-768
34. Jakubzick C., et al. Modulation of dendritic cell trafficking to and from the airways. J. Immunol. 176 (2006) 3578-3584
35. Machida I., et al. Cysteinyl leukotrienes regulate dendritic cell functions in a murine model of asthma. J. Immunol. 172 (2004) 1833-1838
36. Machida I., et al. Effects of various anti-asthmatic agents on mite allergen-pulsed murine bone marrow-derived dendritic cells. Clin. Exp. Allergy 35 (2005) 884-888
37. Humbert M., et al. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy 60 (2005) 309-316
38. Djukanovic R., et al. Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma. Am. J. Respir. Crit. Care Med. 170 (2004) 583-593
39. Maurer D., et al. The high affinity IgE receptor (Fc epsilon RI) mediates IgE-dependent allergen presentation. J. Immunol. 154 (1995) 6285-6290
40. Souness J.E., et al. Evidence that cyclic AMP phosphodiesterase inhibitors suppress TNF alpha generation from human monocytes by interacting with a 'low-affinity' phosphodiesterase 4 conformer. Br. J. Pharmacol. 118 (1996) 649-658
41. Christie P. Roflumilast: a selective phosphodiesterase 4 inhibitor. Drugs Today (Barc.) 41 (2005) 667-675
42. Gantner F., et al. Characterization of the phosphodiesterase (PDE) pattern of in vitro-generated human dendritic cells (DC) and the influence of PDE inhibitors on DC function. Pulm. Pharmacol. Ther. 12 (1999) 377-386
43. Heystek H.C., et al. Phosphodiesterase 4 inhibitors reduce human dendritic cell inflammatory cytokine production and Th1-polarizing capacity. Int. Immunol. 15 (2003) 827-835
44. Kawano T., et al. Tacrolimus reduces urinary excretion of leukotriene E(4) and inhibits aspirin-induced asthma to threshold dose of aspirin. J. Allergy Clin. Immunol. 114 (2004) 1278-1281
45. Stevenson D.D., et al. Failure of tacrolimus to prevent aspirin-induced respiratory reactions in patients with aspirin-exacerbated respiratory disease. J. Allergy Clin. Immunol. 116 (2005) 755-760
46. Lee Y.R., et al. Cyclosporin A and tacrolimus, but not rapamycin, inhibit MHC-restricted antigen presentation pathways in dendritic cells. Blood 105 (2005) 3951-3955
47. Bhattacharjee R.N., and Akira S. Modifying toll-like receptor 9 signaling for therapeutic use. Mini. Rev. Med. Chem. 6 (2006) 287-291
48. Randolph D.A., et al. Modulation of airway inflammation by passive transfer of allergen-specific Th1 and Th2 cells in a mouse model of asthma. J. Immunol. 162 (1999) 2375-2383
49. Gauvreau G.M., et al. Immunostimulatory sequences regulate interferon-inducible genes but not allergic airway responses. Am. J. Respir. Crit. Care Med. 174 (2006) 15-20
50. Hessel E.M., et al. Immunostimulatory oligonucleotides block allergic airway inflammation by inhibiting Th2 cell activation and IgE-mediated cytokine induction. J. Exp. Med. 202 (2005) 1563-1573
51. Hayashi T., et al. Inhibition of experimental asthma by indoleamine 2,3-dioxygenase. J. Clin. Invest. 114 (2004) 270-279
52. Le A.V., and Broide D.H. Indoleamine-2,3-dioxygenase modulation of allergic immune responses. Curr. Allergy Asthma Rep. 6 (2006) 27-31
53. Woerly G., et al. Peroxisome proliferator-activated receptors alpha and gamma down-regulate allergic inflammation and eosinophil activation. J. Exp. Med. 198 (2003) 411-421
54. Usami A., et al. Theophylline and dexamethasone induce peroxisome proliferator-activated receptor-gamma expression in human eosinophils. Pharmacology 77 (2006) 33-37
55. Matsubara S., et al. Syk activation in dendritic cells is essential for airway hyperresponsiveness and inflammation. Am. J. Respir. Cell Mol. Biol. 34 (2006) 426-433
56. Beavitt S.J., et al. Lyn-deficient mice develop severe, persistent asthma: Lyn is a critical negative regulator of Th2 immunity. J. Immunol. 175 (2005) 1867-1875
57. Ridgway D. The first 1000 dendritic cell vaccinees. Cancer Invest. 21 (2003) 873-886
58. Maurer D., et al. Fc epsilon receptor I on dendritic cells delivers IgE-bound multivalent antigens into a cathepsin S-dependent pathway of MHC class II presentation. J. Immunol. 161 (1998) 2731-2739
59. Holgate S., et al. The anti-inflammatory effects of omalizumab confirm the central role of IgE in allergic inflammation. J. Allergy Clin. Immunol. 115 (2005) 459-465
60. Holgate S.T., et al. Anti-immunoglobulin E treatment with omalizumab in allergic diseases: an update on anti-inflammatory activity and clinical efficacy. Clin. Exp. Allergy 35 (2005) 408-416
61. Van Rijt L.S., et al. Respiratory viral infections and asthma pathogenesis: a critical role for dendritic cells?. J. Clin. Virol. 34 (2005) 161-169
62. Van Rijt L.S., and Lambrecht B.N. Dendritic cells in asthma: a function beyond sensitization. Clin. Exp. Allergy 35 (2005) 1125-1134